Xeris Biopharma Holdings (XERS) Stock News
$XERS · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Xeris Biopharma Holdings (XERS) in the past 30 days. BORSA’s news read on XERS is balanced at 50/100, based on 1 company event over the past 7 days. XERS last closed at $10.64 on Oct 28, down 1.34% over five sessions and up 6.61% over the past month. Xeris Biopharma Holdings’ next earnings report is scheduled for Thursday, Nov 5 before the open.
The wire on $XERS
newest first · updated · direct subject stories onlyXeris Biopharma Holdings (Nasdaq: XERS) announced the appointment of Menassie M. Taddese to its Board of Directors, effective November 2, 2026. Taddese, a former Viatris Emerging Markets President and 20-year Pfizer veteran, will also serve on the Board's Audit Committee. The appointment adds governance and financial expertise as Xeris advances its commercial portfolio and late-stage pipeline candidate XP-8121.
neutral 50 · impact 10The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
Xeris Biopharma Holdings (XERS) stock: common questions
What is the latest Xeris Biopharma Holdings stock news?
The highest-impact XERS story BORSA published in the past 30 days:
·